Michigan cancer-fighting biotech spin-out lands $82m in IPO.
OncoMed Pharmaceuticals, a spin-out of the University of Michigan, has raised nearly $82m in an initial public offering (IPO). Founded in 2004, the firm is commercialising cancer-fighting drugs that target stem cells responsible for the growth and metastasis of tumours. The company offered 4.8 million in shares at $17 each, above the expected range. It…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
